Developments CalciMedica announces late-breaking positive data from Phase 2b CARPO trial CalciMedica (NASDAQ:CALC) has announced late-breaking positive data from its Phase 2b CARPO trial of Auxora in acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS). The results are to... October 30, 2024